Literature DB >> 31992930

Effects of powdered rifampin and vancomycin solutions on biofilm production of staphylococcus aureus on orthopedic implants.

Christian Douthit1, Brent Gudenkauf1, Abdul Hamood1, Nithya Mudaliar1, Cyrus Caroom1, Mark Jenkins1.   

Abstract

PURPOSE: Hardware infections in orthopedic surgery, specifically those involving biofilm producing bacteria, are troublesome and are highly resistant to systemic antibiotics. The purpose of this study was to demonstrate the power of rifampin and vancomycin solutions in inhibiting as well as eliminating in vitro on staphylococcus aureus (S. aureus) biofilm in vitro on stainless-steel implants.
METHODS: A suspension of either S. aureus or a S. aureus containing a plasmid that cods for the green fluorescence protein containing fluorescent protein plasmid was applied to 1 × 1cm sterile stainless steel orthopedic plating material (coupon). Biofilm development was confirmed by; the quantitative assay (colony forming unit [CFU/coupon]) and visualized using confocal laser scanning microscopy. With this established method of biofilm development, we determined the minimum biofilm inhibitory concentration (MBIC) and the minimum biofilm eradication concertation (MBEC) of Rifampicin and Vancomycin. To determine the MBIC, stainless steel plates were subjected to different concentrations of antibiotic solution and inoculated with overnight cultures of S. aureus. After 24 h of incubation at 37 °C, the biofilms on the untreated and antibiotic-treated coupons were quantified. To determine the MBEC, partial S. aureus biofilms were developed on the coupons and then treated with the different concentrations of each antibiotic for 24 h. The number of bacteria within the control untreated as well as treated coupons was determined.
RESULTS: Both rifampin and vancomycin solutions inhibited biofilm production of S. aureus on stainless steel mediums; the MBIC for rifampin and vancomycin were 80 ng/mL and 1 μg/mL respectively. The MBEC for Rifampicin was similar to the MBIC. However, the MBEC for Vancomycin was 6 mg/ml.
CONCLUSIONS: When applied to orthopedic stainless steel hardware in vitro, solutions of rifampin and vancomycin powder separately or in combination can completely prevent and eliminate biofilm produced by S. aureus. LEVEL OF EVIDENCE: II.

Entities:  

Keywords:  Biofilm; Infection; Orthopedics; Surgery

Year:  2019        PMID: 31992930      PMCID: PMC6977531          DOI: 10.1016/j.jcot.2019.10.002

Source DB:  PubMed          Journal:  J Clin Orthop Trauma        ISSN: 0976-5662


  14 in total

1.  Quorum sensing in Staphylococcus aureus biofilms.

Authors:  Jeremy M Yarwood; Douglas J Bartels; Esther M Volper; E Peter Greenberg
Journal:  J Bacteriol       Date:  2004-03       Impact factor: 3.490

Review 2.  Orthopaedic biofilm infections.

Authors:  Werner Zimmerli; Parham Sendi
Journal:  APMIS       Date:  2017-04       Impact factor: 3.205

Review 3.  Medical biofilms.

Authors:  James D Bryers
Journal:  Biotechnol Bioeng       Date:  2008-05-01       Impact factor: 4.530

4.  Determining potential of PMMA as a depot for rifampin to treat recalcitrant orthopaedic infections.

Authors:  Stefanie M Shiels; David J Tennent; Kevin S Akers; Joseph C Wenke
Journal:  Injury       Date:  2017-08-16       Impact factor: 2.586

5.  Synergy of combinations of vancomycin, gentamicin, and rifampin against methicillin-resistant, coagulase-negative staphylococci.

Authors:  F D Lowy; D S Chang; P R Lash
Journal:  Antimicrob Agents Chemother       Date:  1983-06       Impact factor: 5.191

6.  Vancomycin displays time-dependent eradication of mature Staphylococcus aureus biofilms.

Authors:  Virginia Post; Peter Wahl; R Geoff Richards; T Fintan Moriarty
Journal:  J Orthop Res       Date:  2016-05-29       Impact factor: 3.494

7.  In vitro anti-biofilm activity of a biphasic gentamicin-loaded calcium sulfate/hydroxyapatite bone graft substitute.

Authors:  Maria Eugenia Butini; Sabrina Cabric; Andrej Trampuz; Mariagrazia Di Luca
Journal:  Colloids Surf B Biointerfaces       Date:  2017-10-18       Impact factor: 5.268

8.  Outcome of hip and knee periprosthetic joint infections caused by pathogens resistant to biofilm-active antibiotics: results from a prospective cohort study.

Authors:  Doruk Akgün; Carsten Perka; Andrej Trampuz; Nora Renz
Journal:  Arch Orthop Trauma Surg       Date:  2018-01-19       Impact factor: 3.067

Review 9.  Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections.

Authors:  Zarique Z Akanda; Mariam Taha; Hesham Abdelbary
Journal:  J Orthop Res       Date:  2017-11-22       Impact factor: 3.494

Review 10.  Biofilms in periprosthetic orthopedic infections.

Authors:  Stephen J McConoughey; Rob Howlin; Jeff F Granger; Maurice M Manring; Jason H Calhoun; Mark Shirtliff; Sandeep Kathju; Paul Stoodley
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

View more
  1 in total

1.  In Vitro Activity of Peptide Antibiotics in Combination With Other Antimicrobials on Extensively Drug-Resistant Acinetobacter baumannii in the Planktonic and Biofilm Cell.

Authors:  Qianlin Meng; Fei Lin; Baodong Ling
Journal:  Front Pharmacol       Date:  2022-05-11       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.